The superiority of anti-fxa assay over anti-fiia assay in detecting heparin-binding site antithrombin deficiency

Bettina Kovács, Z. Bereczky, Zsolt Oláh, Réka Gindele, Adrienne Kerényi, Anna Selmeczi, Z. Boda, L. Muszbek

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Objectives: Antithrombin is a progressive inhibitor of active factor X (FXa) and thrombin (FIIa). Its effect is 500- to 1,000- fold accelerated by heparin or heparan sulfate. Heterozygous type I (quantitative) and most type II (qualitative) antithrombin deficiencies highly increase the risk of venous thromboembolism (VTE), while homozygous mutations are lethal. The functional defect affecting the heparin-binding site confers moderate risk of VTE to heterozygous and high risk of VTE to homozygous individuals. Methods: Antithrombin activity assays based on the inhibition of FIIa and FXa were compared for their efficiency in detecting heparin-binding site defects. Results: With a single exception, in heterozygotes for heparin-binding site defects (n = 20), anti-FIIa activities remained in the reference interval, while anti-FXa activities were uniformly decreased. In individuals who were homozygous for heparin-binding site mutations (n = 9), anti- FIIa activities were in the range of 48% to 80%; the range of anti-FXa activities was 9% to 25%. Anti-FIIa and anti-FXa activities in type I deficiencies and type II pleiotropic deficiency did not differ significantly. Conclusions: Anti-FXa antithrombin assay is recommended as a first-line test to detect type II heparin-binding site antithrombin deficiency.

Original languageEnglish
Pages (from-to)675-679
Number of pages5
JournalAmerican Journal of Clinical Pathology
Volume140
Issue number5
DOIs
Publication statusPublished - Nov 2013

Fingerprint

Antithrombins
Heparin
Binding Sites
Venous Thromboembolism
Factor X
Mutation
Heparitin Sulfate
Heterozygote
Thrombin
FIIa

Keywords

  • Antithrombin
  • Antithrombin deficiency
  • Heparin-binding site defect
  • Thrombophilia

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

The superiority of anti-fxa assay over anti-fiia assay in detecting heparin-binding site antithrombin deficiency. / Kovács, Bettina; Bereczky, Z.; Oláh, Zsolt; Gindele, Réka; Kerényi, Adrienne; Selmeczi, Anna; Boda, Z.; Muszbek, L.

In: American Journal of Clinical Pathology, Vol. 140, No. 5, 11.2013, p. 675-679.

Research output: Contribution to journalArticle

Kovács, Bettina ; Bereczky, Z. ; Oláh, Zsolt ; Gindele, Réka ; Kerényi, Adrienne ; Selmeczi, Anna ; Boda, Z. ; Muszbek, L. / The superiority of anti-fxa assay over anti-fiia assay in detecting heparin-binding site antithrombin deficiency. In: American Journal of Clinical Pathology. 2013 ; Vol. 140, No. 5. pp. 675-679.
@article{e6e08ef776104c2185cdaac23e9583ca,
title = "The superiority of anti-fxa assay over anti-fiia assay in detecting heparin-binding site antithrombin deficiency",
abstract = "Objectives: Antithrombin is a progressive inhibitor of active factor X (FXa) and thrombin (FIIa). Its effect is 500- to 1,000- fold accelerated by heparin or heparan sulfate. Heterozygous type I (quantitative) and most type II (qualitative) antithrombin deficiencies highly increase the risk of venous thromboembolism (VTE), while homozygous mutations are lethal. The functional defect affecting the heparin-binding site confers moderate risk of VTE to heterozygous and high risk of VTE to homozygous individuals. Methods: Antithrombin activity assays based on the inhibition of FIIa and FXa were compared for their efficiency in detecting heparin-binding site defects. Results: With a single exception, in heterozygotes for heparin-binding site defects (n = 20), anti-FIIa activities remained in the reference interval, while anti-FXa activities were uniformly decreased. In individuals who were homozygous for heparin-binding site mutations (n = 9), anti- FIIa activities were in the range of 48{\%} to 80{\%}; the range of anti-FXa activities was 9{\%} to 25{\%}. Anti-FIIa and anti-FXa activities in type I deficiencies and type II pleiotropic deficiency did not differ significantly. Conclusions: Anti-FXa antithrombin assay is recommended as a first-line test to detect type II heparin-binding site antithrombin deficiency.",
keywords = "Antithrombin, Antithrombin deficiency, Heparin-binding site defect, Thrombophilia",
author = "Bettina Kov{\'a}cs and Z. Bereczky and Zsolt Ol{\'a}h and R{\'e}ka Gindele and Adrienne Ker{\'e}nyi and Anna Selmeczi and Z. Boda and L. Muszbek",
year = "2013",
month = "11",
doi = "10.1309/AJCPVY4Z9XZMFOTH",
language = "English",
volume = "140",
pages = "675--679",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "5",

}

TY - JOUR

T1 - The superiority of anti-fxa assay over anti-fiia assay in detecting heparin-binding site antithrombin deficiency

AU - Kovács, Bettina

AU - Bereczky, Z.

AU - Oláh, Zsolt

AU - Gindele, Réka

AU - Kerényi, Adrienne

AU - Selmeczi, Anna

AU - Boda, Z.

AU - Muszbek, L.

PY - 2013/11

Y1 - 2013/11

N2 - Objectives: Antithrombin is a progressive inhibitor of active factor X (FXa) and thrombin (FIIa). Its effect is 500- to 1,000- fold accelerated by heparin or heparan sulfate. Heterozygous type I (quantitative) and most type II (qualitative) antithrombin deficiencies highly increase the risk of venous thromboembolism (VTE), while homozygous mutations are lethal. The functional defect affecting the heparin-binding site confers moderate risk of VTE to heterozygous and high risk of VTE to homozygous individuals. Methods: Antithrombin activity assays based on the inhibition of FIIa and FXa were compared for their efficiency in detecting heparin-binding site defects. Results: With a single exception, in heterozygotes for heparin-binding site defects (n = 20), anti-FIIa activities remained in the reference interval, while anti-FXa activities were uniformly decreased. In individuals who were homozygous for heparin-binding site mutations (n = 9), anti- FIIa activities were in the range of 48% to 80%; the range of anti-FXa activities was 9% to 25%. Anti-FIIa and anti-FXa activities in type I deficiencies and type II pleiotropic deficiency did not differ significantly. Conclusions: Anti-FXa antithrombin assay is recommended as a first-line test to detect type II heparin-binding site antithrombin deficiency.

AB - Objectives: Antithrombin is a progressive inhibitor of active factor X (FXa) and thrombin (FIIa). Its effect is 500- to 1,000- fold accelerated by heparin or heparan sulfate. Heterozygous type I (quantitative) and most type II (qualitative) antithrombin deficiencies highly increase the risk of venous thromboembolism (VTE), while homozygous mutations are lethal. The functional defect affecting the heparin-binding site confers moderate risk of VTE to heterozygous and high risk of VTE to homozygous individuals. Methods: Antithrombin activity assays based on the inhibition of FIIa and FXa were compared for their efficiency in detecting heparin-binding site defects. Results: With a single exception, in heterozygotes for heparin-binding site defects (n = 20), anti-FIIa activities remained in the reference interval, while anti-FXa activities were uniformly decreased. In individuals who were homozygous for heparin-binding site mutations (n = 9), anti- FIIa activities were in the range of 48% to 80%; the range of anti-FXa activities was 9% to 25%. Anti-FIIa and anti-FXa activities in type I deficiencies and type II pleiotropic deficiency did not differ significantly. Conclusions: Anti-FXa antithrombin assay is recommended as a first-line test to detect type II heparin-binding site antithrombin deficiency.

KW - Antithrombin

KW - Antithrombin deficiency

KW - Heparin-binding site defect

KW - Thrombophilia

UR - http://www.scopus.com/inward/record.url?scp=84886299333&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886299333&partnerID=8YFLogxK

U2 - 10.1309/AJCPVY4Z9XZMFOTH

DO - 10.1309/AJCPVY4Z9XZMFOTH

M3 - Article

VL - 140

SP - 675

EP - 679

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 5

ER -